Macedonia will fund Spinraza treatment

The government of Macedonia has agreed to provide Spinraza treatment to all those with spinal muscular atrophy.

The Macedonian SMA organisation STOP-SMA, which has worked on connecting the Macedonian government and the manufacturer, recently announced that the treatment will soon be available to all those with SMA in Macedonia, and the Macedonian Prime Minister has confirmed this.

The Republic of Macedonia is a small Balcan country of 2.1 million people. Its GDP per capita is around 8 times lower than the UK and its government per capita health expenditure around 18 times lower in absolute terms. We sincerely congratulate the Macedonian families on these fortunate developments.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more